Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Maarten, Leyssen"'
Autor:
Viki Bockstal, Maarten Leyssen, Dirk Heerwegh, Bart Spiessens, Cynthia Robinson, Jeroen N. Stoop, Ramon Roozendaal, Thierry Van Effelterre, Auguste Gaddah, Griet A. Van Roey, Laura Solforosi, Roland Zahn, Benoit Callendret, Jenny Hendriks, Kerstin Luhn, Macaya Douoguih, Hanneke Schuitemaker, Johan Van Hoof
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-8 (2022)
Abstract Without clinical efficacy data, vaccine protective effect may be extrapolated from animals to humans using an immunologic marker that correlates with protection in animals. This immunobridging approach was used for the two-dose Ebola vaccine
Externí odkaz:
https://doaj.org/article/62001c2a26ba43fdbeac3ea1080907ee
Autor:
Etienne Karita, Julien Nyombayire, Rosine Ingabire, Amelia Mazzei, Tyronza Sharkey, Jeannine Mukamuyango, Susan Allen, Amanda Tichacek, Rachel Parker, Frances Priddy, Felix Sayinzoga, Sabin Nsanzimana, Cynthia Robinson, Michael Katwere, Dickson Anumendem, Maarten Leyssen, Malinda Schaefer, Kristin M. Wall
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-23 (2022)
Abstract Background Risks to mother and fetus following Ebola virus infection are very high. Evaluation of safety and immunogenicity of non-replicating Ebola vaccine candidates is a priority for use in pregnant women. This is the protocol for a rando
Externí odkaz:
https://doaj.org/article/38e58ac027044ca4bd84f54a7a41ccf5
Autor:
Viki Bockstal, Auguste Gaddah, Neil Goldstein, Georgi Shukarev, Stephan Bart, Kerstin Luhn, Cynthia Robinson, Dickson Anumendem, Maarten Leyssen, Macaya Douoguih
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-14 (2021)
Abstract Two phase 3 clinical studies were conducted in the USA to bridge across different Ad26.ZEBOV manufacturing processes and sites, and to evaluate the immunogenicity of different dose levels of Ad26.ZEBOV and MVA-BN-Filo. Study 1 evaluated the
Externí odkaz:
https://doaj.org/article/7c2795f7e19c4f3e9ae22a1cfba61a16
Autor:
Ramon Roozendaal, Jenny Hendriks, Thierry van Effelterre, Bart Spiessens, Liesbeth Dekking, Laura Solforosi, Dominika Czapska-Casey, Viki Bockstal, Jeroen Stoop, Daniel Splinter, Sarah Janssen, Ben van Baelen, Nadia Verbruggen, Jan Serroyen, Eline Dekeyster, Ariane Volkmann, Yvonne Wollmann, Ricardo Carrion, Luis D. Giavedoni, Cynthia Robinson, Maarten Leyssen, Macaya Douoguih, Kerstin Luhn, Maria Grazia Pau, Jerry Sadoff, An Vandebosch, Hanneke Schuitemaker, Roland Zahn, Benoit Callendret
Publikováno v:
npj Vaccines, Vol 5, Iss 1, Pp 1-11 (2020)
Abstract It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV) vaccines. In the absence of efficacy data, immunobridging is an approach to infer the likelihood of a vaccine protective effect, by translating vacc
Externí odkaz:
https://doaj.org/article/31753f8ec19c4f7ca129201ac99ccb00
Autor:
Deborah Watson-Jones, Shelley Lees, Brian Greenwood, Daniel G Bausch, Peter G Smith, Chrissy H Roberts, Nathalie Imbault, Anton Camacho, W John Edmunds, Eric Delaporte, Melanie Saville, John Johnson, Ira M Longini, Hugo Kavunga-Membo, Rebecca F Grais, Steve Ahuka, Natalie Roberts, Edward M Choi, Tansy Edwards, Maarten Leyssen, Bart Spiessens, Kerstin Luhn, Macaya Douoguih, Richard Hatchett, Jean-Jacques Muyembe, Daniela Manno, Rebecca Grais, Susan Rattigan, Grace Mambula, Patient Mumbere Kighoma, Marie Burton, Gerald Voss
Publikováno v:
BMJ Open, Vol 12, Iss 3 (2022)
Introduction Ebola virus disease (EVD) continues to be a significant public health problem in sub-Saharan Africa, especially in the Democratic Republic of the Congo (DRC). Large-scale vaccination during outbreaks may reduce virus transmission. We est
Externí odkaz:
https://doaj.org/article/feb851d7c82345b98475c0dfc92d5f92
Autor:
Zacchaeus Anywaine, Houreratou Barry, Omu Anzala, Gaudensia Mutua, Sodiomon B. Sirima, Serge Eholie, Hannah Kibuuka, Christine Bétard, Laura Richert, Christine Lacabaratz, M. Juliana McElrath, Stephen C. De Rosa, Kristen W. Cohen, Georgi Shukarev, Michael Katwere, Cynthia Robinson, Auguste Gaddah, Dirk Heerwegh, Viki Bockstal, Kerstin Luhn, Maarten Leyssen, Rodolphe Thiébaut, Macaya Douoguih, on behalf of the EBL2002 Study group
Publikováno v:
PLoS Medicine, Vol 19, Iss 1 (2022)
Background Reoccurring Ebola outbreaks in West and Central Africa have led to serious illness and death in thousands of adults and children. The objective of this study was to assess safety, tolerability, and immunogenicity of the heterologous 2-dose
Externí odkaz:
https://doaj.org/article/e1f49a02b0c94e9ba66ed470427070ec
Autor:
Houreratou Barry, Gaudensia Mutua, Hannah Kibuuka, Zacchaeus Anywaine, Sodiomon B. Sirima, Nicolas Meda, Omu Anzala, Serge Eholie, Christine Bétard, Laura Richert, Christine Lacabaratz, M. Juliana McElrath, Stephen De Rosa, Kristen W. Cohen, Georgi Shukarev, Cynthia Robinson, Auguste Gaddah, Dirk Heerwegh, Viki Bockstal, Kerstin Luhn, Maarten Leyssen, Macaya Douoguih, Rodolphe Thiébaut, the EBL2002 Study group
Publikováno v:
PLoS Medicine, Vol 18, Iss 10 (2021)
Background We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. Methods and findings In this randomised,
Externí odkaz:
https://doaj.org/article/7f50b4c25b664eea9599a273130f7e74
Autor:
Muhammed O Afolabi, David Ishola, Daniela Manno, Babajide Keshinro, Viki Bockstal, Baimba Rogers, Kwabena Owusu-Kyei, Alimamy Serry-Bangura, Ibrahim Swaray, Brett Lowe, Dickens Kowuor, Frank Baiden, Thomas Mooney, Elizabeth Smout, Brian Köhn, Godfrey T Otieno, Morrison Jusu, Julie Foster, Mohamed Samai, Gibrilla Fadlu Deen, Heidi Larson, Shelley Lees, Neil Goldstein, Katherine E Gallagher, Auguste Gaddah, Dirk Heerwegh, Benoit Callendret, Kerstin Luhn, Cynthia Robinson, Brian Greenwood, Maarten Leyssen, Macaya Douoguih, Bailah Leigh, Deborah Watson-Jones, M Kargbo, E Bockarie, N L James, A Kabbah, A Kamara, K H Koroma, S O Langley, N William, R Kessebeh, T Mooney, L Conteh, E Smout, K Allieu, K Bangura, M S Bangura, M A Bangura, H Jalloh, A B Jalloh, I Kamara, M Kamara, A Konteh, S Koroma, C Marrah, M Sesay, M T Sesay, A T Deen, A Jalloh, R M Kaimbay, D Kain, E L Kamara, M P Kamara, O J Kamara, S L M Kamara, M Kanneh, A H Koroma, D Lahai, I S Mansaray, W S Marah, M J Massaquoi, A Nabie, N S Saidu, I Samai, J N Tengheh, A S Turay, A Fornah, F Sesay, A Sow, E Swaray, F Mansaray, T Ade-Cole, L M Bangura, M L Conteh, A M Koroma, M Koroma, A Sam, T Scott, T Sessie, J-H C Sunders, S I-S Turay, J Weekes, M Sheku, L Gibson, D Kowuor, I Ahamed, W Allieu, D U Kabba, F J Kamara, M S Kebbie, M Pessima, A Wurie, F Bah, A I Bangura, R A S Bangura, L Blango, S Boima, M Conteh, Y Conteh, M L Daramy, O Fofanah, E George, T F Hanson, M I Jalloh, M Kalawa, A M Kamara, F E Kamara, G M Kamara, H M Kamara, P B D Kamara, R T Kamara, R Kamara, D P Kanneh, I Komeh, M Kuyateh, F F Mansaray, M M Mansaray, A B Sillah, M A Tarawally, O S Turya, J B Yawmah, B Leigh, D Watson-Jones, B Greenwood, M H Samai, G F Deen, D Marke, T Sesay, P Piot, P Smith, J Edmunds, S Lees, H Larson, H Weiss, P Wilson, R Phillips, C Maxwell, D Ishola, M Afolabi, F Baiden, P Akoo, K Owusu-Kyei, D Tindanbil, H Bower, J Stuart, O M Bah, B T Rogers, A Serry-Bangura, I B Swaray, A Bangura, I J David, D G M Davies, J A Kallon, A B Kamara, I F Kamara, M M Kamara, F E Morovia, F B Suma, F Thompson, M Murray, O Kakay, F Suma, I Sesay, J Foster, D Manno, K Gallagher, S Cox, N Howard, M Cesay, P Torrani, S Sharma, E Snowden, T Banks, T Harber, J Brown, K Howard, N Melton, S Malcolm, S Welsh, R Eggo, M Jendrossek, C Pearson, K Offergeld, C Ferrault, M Van Alst, N Mahajan, M Van Looveren, S Van Ballaert, T De Cnodder, N Grobler, L Roza, T Liberi, L Armishaw, C Verkleij, T Henrick, A Banaszkiewicz, B Lowe, K Awuondo, H Hafezi, E Hancox, B Kohn, G O Tuda, G Bangura, M T Kroma, L Fofanah, A Pessima, M Rogers, O Sheriff, T W Ajala, J Fangawa, S Foday Jr, I S F Koroma, B Mansaray, H A Mansaray, K Sesay, M K Charles, P C Heroe, M Lamin Karbo, I S Yansaneh, S Gogo Egoeh, A Trye, M Amponsah, L Donelson, T Sylvester, V Owira, G Onyuka, L Nambuchi, A Oburu, D Apollo, L Vandi, N D Alghali, A Bah, I J Bangura, A C Cole, S Fofanah, H U Jalloh, K F N Jalloh, N Jalloh, H U Kabba, J N Kabba, M Kabba, J S Kamara, F Kanjie, A P Kanu, I Kargbo, G Kassa-Koroma, S B Koroma, A Sankoh, T Sankoh, O D Sesay, H Wilhem, C T Williams, I Bangura, Y Ben-Rogers, F J Jamboria, N Kamara, I Kanawah, A T Kargbo, I Swaray, L Amara, I Bundu, H B Jakema, K Kamara, M F Sheku, Q Adeleye, I Akhigbe, R Bakalemwa, N P Chami, L Altmann, B Kamara, K van Roey, P Conteh, M Samura, V Gandie, M Marrah, E Moinina, J Kalokoh, S Bosompem, T Hilton, M O Jusu, P Borboh, A S Brima, A F Y Caulker, A Kallon, B Koroma, R C Macauley, T M D Saquee, H I Williams, A R Bangura, J Fornah, B Idriss, M Sillah, W Mackay, B Aleghen, T Murray, J Edem-Hotah, T Fatorma, F Amara, S Bangura, E Bonnie, M Sannoh, A Donaldson, S Ndingi, D Nyaberi, M Pereira, A Rothwell, V Vy, L Nyallay, A Fombah, S Saidu, T P Dambo, P J Fakaba, M M E Fatorma, R H Freeman, C L Johnson, D B Kogba, A Lahai, W Vincent, N Yambasu, M Bangura, A Tengbeh, R Kabia, A M Nyakoi, M Callaghan, L Enria, S Lee
Publikováno v:
The Lancet Infectious Diseases. 22:110-122
Summary Background Children account for a substantial proportion of cases and deaths from Ebola virus disease. We aimed to assess the safety and immunogenicity of a two-dose heterologous vaccine regimen, comprising the adenovirus type 26 vector-based
Autor:
Roland Zahn, Carlos Fierro, Maarten Leyssen, Marrit N. Habets, Kayvon Modjarrad, Rafael A. Larocca, Carla Truyers, Hanneke Schuitemaker, Leslie van der Fits, Diane G. Kanjilal, Kristi Lynn Williams, Nadine C. Salisch, Jenny Hendriks, Kathryn E. Stephenson, Macaya Douoguih, Johan Van Hoof, Dan H. Barouch, Conor P. Cahill, Freek Cox, Dirk Heerwegh, Jinyan Liu, Peter Abbink, Lauren Peter, Rafael De La Barrera
Publikováno v:
Annals of Internal Medicine. 174:585-594
BACKGROUND: Zika virus (ZIKV) may cause severe congenital disease after maternal-fetal transmission. No vaccine is currently available. OBJECTIVE: To assess the safety and immunogenicity of Ad26.ZIKV.001, a prophylactic ZIKV vaccine candidate. DESIGN
Autor:
Bart Spiessens, Ramon Roozendaal, Liesbeth Dekking, Maria Grazia Pau, Cynthia Robinson, Dominika N. Czapska-Casey, Yvonne Wollmann, Thierry Van Effelterre, Viki Bockstal, Eline Dekeyster, Roland Zahn, Jeroen N Stoop, Kerstin Luhn, Jan Serroyen, Luis D. Giavedoni, Jenny Hendriks, Sarah Janssen, Maarten Leyssen, Ben Van Baelen, Hanneke Schuitemaker, Ricardo Carrion, Daniel Splinter, An Vandebosch, Jerry Sadoff, Ariane Volkmann, Nadia Verbruggen, Macaya Douoguih, Laura Solforosi, Benoit Callendret
Publikováno v:
NPJ VACCINES
npj Vaccines
NPJ Vaccines
npj Vaccines, Vol 5, Iss 1, Pp 1-11 (2020)
npj Vaccines
NPJ Vaccines
npj Vaccines, Vol 5, Iss 1, Pp 1-11 (2020)
It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV) vaccines. In the absence of efficacy data, immunobridging is an approach to infer the likelihood of a vaccine protective effect, by translating vaccine immun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a435e1265a441954725ed3930a761f9
http://hdl.handle.net/1887/3562934
http://hdl.handle.net/1887/3562934